Nile Therapeutics, Inc. Stock Other OTC
Equities
US6541451018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
05-13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Sales 2024 * | 26.58M 36.36M | Sales 2025 * | 78.61M 108M | Capitalization | 179M 245M |
---|---|---|---|---|---|
Net income 2024 * | -33M -45.15M | Net income 2025 * | -4M -5.47M | EV / Sales 2024 * | 6.75 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.28 x |
P/E ratio 2024 * |
-5.45
x | P/E ratio 2025 * |
-24.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.74% |
Latest transcript on Nile Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
1st Jan change | Capi. | |
---|---|---|
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.31% | 22.48B | |
-9.74% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |